DE2635293A1 - Salzgemisch, insbesondere leicht assimilierbares arzneimittelgemisch mit erhoehter loeslichkeit, enthaltend kalziumsalze und/oder magnesiumsalze - Google Patents
Salzgemisch, insbesondere leicht assimilierbares arzneimittelgemisch mit erhoehter loeslichkeit, enthaltend kalziumsalze und/oder magnesiumsalzeInfo
- Publication number
- DE2635293A1 DE2635293A1 DE19762635293 DE2635293A DE2635293A1 DE 2635293 A1 DE2635293 A1 DE 2635293A1 DE 19762635293 DE19762635293 DE 19762635293 DE 2635293 A DE2635293 A DE 2635293A DE 2635293 A1 DE2635293 A1 DE 2635293A1
- Authority
- DE
- Germany
- Prior art keywords
- magnesium
- calcium
- salts
- mixture
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims description 23
- 159000000007 calcium salts Chemical class 0.000 title claims description 10
- 159000000003 magnesium salts Chemical class 0.000 title claims description 10
- 239000011833 salt mixture Substances 0.000 title claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000000889 atomisation Methods 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 241000845077 Iare Species 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 34
- 239000000047 product Substances 0.000 description 16
- 239000001755 magnesium gluconate Substances 0.000 description 13
- 229960003035 magnesium gluconate Drugs 0.000 description 13
- 235000015778 magnesium gluconate Nutrition 0.000 description 13
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 13
- 239000000626 magnesium lactate Substances 0.000 description 13
- 235000015229 magnesium lactate Nutrition 0.000 description 13
- 229960004658 magnesium lactate Drugs 0.000 description 13
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 10
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 10
- 239000001527 calcium lactate Substances 0.000 description 10
- 235000011086 calcium lactate Nutrition 0.000 description 10
- 239000011777 magnesium Substances 0.000 description 10
- 229910052749 magnesium Inorganic materials 0.000 description 10
- 235000001055 magnesium Nutrition 0.000 description 10
- 229940091250 magnesium supplement Drugs 0.000 description 10
- 229960005069 calcium Drugs 0.000 description 9
- 239000004227 calcium gluconate Substances 0.000 description 9
- 235000013927 calcium gluconate Nutrition 0.000 description 9
- 229960004494 calcium gluconate Drugs 0.000 description 9
- 229960002401 calcium lactate Drugs 0.000 description 9
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 9
- 229960002079 calcium pantothenate Drugs 0.000 description 8
- ONSCBWDZUUNMMK-UBKPKTQASA-L magnesium;3-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound [Mg+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O ONSCBWDZUUNMMK-UBKPKTQASA-L 0.000 description 8
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 6
- 235000013918 magnesium diglutamate Nutrition 0.000 description 5
- 229940063886 magnesium glutamate Drugs 0.000 description 5
- MYUGVHJLXONYNC-QHTZZOMLSA-J magnesium;(2s)-2-aminopentanedioate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O MYUGVHJLXONYNC-QHTZZOMLSA-J 0.000 description 5
- 238000002156 mixing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- -1 magnesium lactate Calcium glutamate Chemical compound 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000013921 calcium diglutamate Nutrition 0.000 description 2
- XKWSPSJAZUSXFV-UHFFFAOYSA-J calcium magnesium 2-hydroxypropanoate Chemical compound [Mg++].[Ca++].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O XKWSPSJAZUSXFV-UHFFFAOYSA-J 0.000 description 2
- UMVAYAXXQSFULN-QHTZZOMLSA-L calcium;(2s)-2-aminopentanedioate;hydron Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CCC(O)=O.[O-]C(=O)[C@@H](N)CCC(O)=O UMVAYAXXQSFULN-QHTZZOMLSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102220577237 Density-regulated protein_G88Y_mutation Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940041131 calcium lactate gluconate Drugs 0.000 description 1
- 229940078480 calcium levulinate Drugs 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- RTJBZRZWQWOEAM-UHFFFAOYSA-L calcium magnesium 2-hydroxypropanoate Chemical compound C(C(O)C)(=O)[O-].[Ca+2].C(C(O)C)(=O)[O-].[Mg+2] RTJBZRZWQWOEAM-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- LVBYARIAGHDPEA-UHFFFAOYSA-J dimagnesium 2-hydroxypropanoate Chemical compound [Mg+2].[Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O LVBYARIAGHDPEA-UHFFFAOYSA-J 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 229940021384 salt irrigating solution Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO7583091A RO68298A2 (ro) | 1975-08-05 | 1975-08-05 | Compozitie pe baza de saruri organice de calciu si magneziu usor asimilabile si cu o solubilitate crescuta,si procedeu de preparare a acesteia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2635293A1 true DE2635293A1 (de) | 1977-05-12 |
Family
ID=20095205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762635293 Withdrawn DE2635293A1 (de) | 1975-08-05 | 1976-08-05 | Salzgemisch, insbesondere leicht assimilierbares arzneimittelgemisch mit erhoehter loeslichkeit, enthaltend kalziumsalze und/oder magnesiumsalze |
Country Status (7)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU84891A1 (fr) * | 1983-06-30 | 1985-03-29 | Continental Pharma | Derives de l'acide 2-aminoacetique,leur preparation et utilisation ainsi que compositions pharmaceutiques contenant ces derives |
| JP2891744B2 (ja) * | 1989-04-19 | 1999-05-17 | 武田薬品工業株式会社 | パントテン酸カルシウム組成物およびその製造方法 |
| GB8926486D0 (en) * | 1989-11-23 | 1990-01-10 | Ciba Geigy | Pesticide composition |
| CN101209962B (zh) * | 2006-12-28 | 2011-08-24 | 浙江山下湖珍珠集团股份有限公司 | 一种葡萄糖酸钙镁的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2454164A1 (de) * | 1974-11-15 | 1976-05-26 | Tad Pharm Werk | Injektions- bzw. infusionsloesung zur bekaempfung von tetanien bei wiederkaeuern und verfahren zur herstellung derselben |
-
1975
- 1975-08-05 RO RO7583091A patent/RO68298A2/ro unknown
-
1976
- 1976-07-29 GB GB31669/76A patent/GB1564135A/en not_active Expired
- 1976-08-03 CH CH987476A patent/CH625503A5/de not_active IP Right Cessation
- 1976-08-03 IN IN1379/CAL/1976A patent/IN144366B/en unknown
- 1976-08-05 DE DE19762635293 patent/DE2635293A1/de not_active Withdrawn
- 1976-08-05 FR FR7623930A patent/FR2320089A1/fr active Granted
- 1976-08-05 JP JP9442676A patent/JPS54122216A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2454164A1 (de) * | 1974-11-15 | 1976-05-26 | Tad Pharm Werk | Injektions- bzw. infusionsloesung zur bekaempfung von tetanien bei wiederkaeuern und verfahren zur herstellung derselben |
Non-Patent Citations (1)
| Title |
|---|
| Helwig, B.: Moderne Arzneimittel, Stuttgart 1972, S. 126, 127, 219, 220, 301 u. 303 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2320089A1 (fr) | 1977-03-04 |
| FR2320089B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1978-11-17 |
| IN144366B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1978-04-29 |
| JPS5761728B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1982-12-25 |
| JPS54122216A (en) | 1979-09-21 |
| RO68298A2 (ro) | 1980-04-15 |
| GB1564135A (en) | 1980-04-02 |
| CH625503A5 (en) | 1981-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69409969T2 (de) | Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen | |
| DD157561A5 (de) | Verfahren zur herstellung von mucopolysacchariden | |
| DE2634900B1 (de) | 3-trihydroxygermylpropionsaeure, ihre salze und verfahren zu deren herstellung | |
| DE2945790A1 (de) | Neutrales kristallines salz einer basischen l-aminosaeure mit l-apfelsaeure und verfahren zu dessen herstellung | |
| CH621065A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3832638C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2433209A1 (de) | Hitzestabile plasmaproteinloesungen, verfahren zu ihrer herstellung und arzneipraeparate | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE68903059T2 (de) | Strontiumsalz, verfahren zu dessen herstellung und arzneimittel, die es enthalten. | |
| DE2635293A1 (de) | Salzgemisch, insbesondere leicht assimilierbares arzneimittelgemisch mit erhoehter loeslichkeit, enthaltend kalziumsalze und/oder magnesiumsalze | |
| CH624098A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE1806926A1 (de) | Lithiumsalz der Hydrochinonsulfonsaeure | |
| DE3212909C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| DE69426317T2 (de) | Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation | |
| DE2443492A1 (de) | Mittel zur behandlung der atmungswege | |
| DE2951132C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE1911240B2 (de) | Antibioticum 20 798 RP, Verfahren zu seiner Gewinnung und Arzneimittel, die dieses enthalten | |
| DE4447352C2 (de) | Verfahren zur Herstellung Galactose enthaltender Zubereitungen für die enterale und parenterale Ernährung von Patienten | |
| DE1296306B (de) | Verfahren zur Gewinnung von Proteinstoffen mit biologischer Wirkung auf das Nervensystem | |
| DE2245826C3 (de) | Salze von N-Cyano-äthyl-N'-m-chlorphenyl-piperazin | |
| DE942534C (de) | Verfahren zur Herstellung von haltbaren und gut wirksamen Loesungen oder Suspensionen antibiotischer Mittel | |
| DE1000963C2 (de) | Verfahren zur Herstellung von biologisch aktiven, Vitamine der B-Gruppe enthaltenden Zubereitungen | |
| DE2307795C3 (de) | 11 beta 17alpha, 21 Trihydroxy-6 | |
| DE2305735C2 (de) | L-Lysin-Carbamat, Verfahren zu dessen Herstellung und dessen Verwendung in Brausemischungen und Brausemedikamenten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8128 | New person/name/address of the agent |
Representative=s name: REINHARD, H., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., |
|
| 8139 | Disposal/non-payment of the annual fee |